Junaliza

Atorvastatin/Ezetimibe, the active ingredients in Junaliza, are a statin and cholesterol absorption inhibitor presented as an oral tablet for systemic use. They reduce elevated low‑density lipoprotein cholesterol and triglycerides in adults with primary hyperlipidemia, mixed dyslipidemia, or familial hypercholesterolemia.

GNH USA supplies Junaliza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution to meet the needs of healthcare providers across multiple markets and regulatory.

Junaliza combines atorvastatin and ezetimibe to lower lipid levels in disorders of cholesterol metabolism. - Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol in patients with elevated cholesterol. - Mixed dyslipidemia: improves both LDL‑cholesterol and triglyceride levels in individuals with combined lipid abnormalities. - Familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when diet and statin monotherapy are insufficient.

Junaliza may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported. - Myalgia: muscle aches without significant CK elevation. - Diarrhea: loose stools or increased bowel movements. - Nausea: occasional feeling of sickness. - Elevated liver enzymes: mild transaminase increases.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with high CK. - Hepatotoxicity: marked elevation of liver enzymes or hepatitis. - Acute renal failure: sudden loss of kidney function. - Anaphylactic reaction: rare severe allergic response. - Interstitial lung disease: uncommon pulmonary inflammation.

Before prescribing Junaliza, clinicians should consider several precautionary measures to ensure safe use. - Liver function monitoring: assess baseline transaminases and repeat periodically. - Renal impairment: adjust therapy in patients with severe kidney disease. - Drug interactions: review concomitant medications that affect statin metabolism. - Pregnancy and lactation: avoid use due to unknown safety profile. - Muscle toxicity: discontinue if signs of myopathy or rhabdomyolysis appear. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Junaliza can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase atorvastatin exposure and risk of muscle toxicity. - Gemfibrozil: markedly raises statin levels, heightening rhabdomyolysis risk. - Cyclosporine: enhances both components, leading to hepatotoxicity and myopathy.

Moderate Interactions (Monitor Closely): - Antacids (e.g., aluminum hydroxide): may reduce ezetimibe absorption. - Warfarin: potential alteration of INR, requiring closer monitoring. - Niacin: additive lipid‑lowering effect may increase muscle side effects.